Risedronic Acid

CHEMBL923 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

283.1 g/mol

LogP

-3.1

Phase

4

Risedronic acid (risedronate) is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone matrix and inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway of osteoclasts, impairing their function and inducing apoptosis. It is used for the prevention and treatment of osteoporosis, glucocorticoid-induced osteoporosis, Paget's disease of bone, and skeletal complications of malignancy including bone metastases.

Molecular Weight

283.1100 g/mol

LogP

-3.10

TPSA

148.00 Å²

Lipinski RO5

Pass

Therapeutic Areas

Breast Cancer Epilepsy Leukemia Lymphoma Osteoporosis Prostate Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

O=P(O)(O)C(O)(Cc1cccnc1)P(=O)(O)O

InChI

InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)

Molecular Formula

C7H11NO7P2

HBD / HBA

5 / 8

Rotatable Bonds

4

Heavy Atoms

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

Risedronic acid (risedronate) is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone matrix and inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway of osteoclasts, impairing their function and inducing apoptosis. It is used for the prevention and treatment of osteoporosis, glucocorticoid-induced osteoporosis, Paget's disease of bone, and skeletal complications of malignancy including bone metastases.

Yes, Risedronic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL923. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5245. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Looking for patient-friendly information?

Risedronic Acid on PillFYI

Structure

Quick Data

Formula: C7H11NO7P2

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.